You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
HEPARIN PLATELET FACTOR IGG ANTIBODY |
||
Geisinger Epic Procedure Code: LAB2427
Geisinger Epic ID: 31824
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum (preferred) or sodium citrate plasma also acceptable. | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
2.7 mL blue-top (3.2% sodium citrate) tube
|
|
Specimen required: |
0.5 mL aliquot serum (preferred) or plasma; minimum 0.2 mL | |
Special notes: |
For same day testing, specimen must be received in Immunology Laboratory by noon. Specimens received after that time will be tested on the next testing day. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow serum to clot. Centrifuge and submit 0.5 mL aliquot of serum (preferred) or plasma. | |
Transport temperature: |
Refrigerated (preferred). Room temperature (stable 8 hours) and frozen specimens also acceptable. | |
Specimen stability: |
Room temperature: 8 hours. 2-8°C: 48 hours. Frozen: 6 months. | |
Rejection criteria: |
Specimen stability exceeded; specimen grossly hemolyzed. | |
TEST DETAILS |
||
Reference interval: |
<0.400 | |
CPT code(s): |
86022 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Polyspecific (IgG, A, and M) antibody to platelet factor 4. | |
Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
|
Synonyms: |
Heparin-induced thrombocytopenia Ab to platelet factor 4 HIT, Anti-platelet factor 4, Anti-PF4 HAT, heparin-induced thrombocytopenia GAM Heparin-associated antibody HITGAM
|
|
Clinical significance: |
Heparin-induced thrombocytopenia (HIT) is the most common form of drug-induced thrombocytopenia and can develop in up to 5% of patients treated with heparin. A presumptive diagnosis of HIT can be based on a > 50% reduction in platelet count more than 5 days after initiation of heparin therapy, a platelet count <150,000/uL or the development of thromboembolic complications. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu PhD, DABCC, FADLM | |
| Review Date: | 12/13/2022 | |